Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

NCT03824002 · Completed

Last updated 2026-05-28

This clinical trial tests the effects of dulaglutide on blood vessel function in adults with diabetes by measuring changes in arterial stiffness and blood flow over 3 and 9 months.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 92 people

Who can join Ages 18–90 · all sexes Healthy volunteers accepted.

Timeline Started 2017-04 · est. completion 2018-04

Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT03824002 ↗

Description as written by the study sponsor.

The study aims to evaluate arterial stiffness and endothelial function indexes and their relationship with clinic and laboratory varible in a group of diabetic patients in treatment with dulaglutide

Treatments tested

Dulaglutide also known as aspart insulin, glargine insulin, metformin, repaglinide Drug

Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
Aspart insulin Drug

Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Glargine Drug

Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Metformin Drug

Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Repaglinide Drug

Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Main thing measured	Change from Baseline Reactive Hyperemia Index at 3 and 9 months
Sponsor	University of Palermo
Conditions studied	Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03824002 ↗